The SURPASS-2 Trial: Tirzepatide vs. Semaglutide for Diabetes

Part of the DietApp.com GLP-1 Trial Database, a comprehensive, regularly reviewed resource.

What It Is

SURPASS-2 was the first head-to-head trial directly comparing tirzepatide against injectable semaglutide, specifically in adults with type 2 diabetes already on metformin. It predates SURMOUNT-5, which made the equivalent comparison in a weight-management population without diabetes.

Key Results

SURPASS-2 established tirzepatide's superiority over semaglutide 1 mg for both A1C reduction and weight loss in this population. This result was influential enough to be cited in broader diabetes treatment recommendations, given how directly it compared two leading GLP-1-class medications in a single trial.

A Genuine Tradeoff Worth Knowing

Discontinuation due to side effects was notably higher with tirzepatide than semaglutide in this trial, about 6% at the 5 mg dose and up to 8.5% at the 10 or 15 mg doses, compared to 4.1% in the semaglutide 1 mg group. This is a meaningful, specific data point for anyone weighing greater average effectiveness against a real difference in tolerability, not simply which drug is better in the abstract.

Broader Context: SURPASS-CVOT

A related trial, SURPASS-CVOT, involving over 13,000 adults with type 2 diabetes and established cardiovascular disease, found tirzepatide non-inferior to dulaglutide for major cardiovascular events, contributing cardiovascular safety data for tirzepatide, an area where semaglutide still has a longer track record through SUSTAIN-6 and SELECT.

References

• PMC: Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
• Frontiers in Medicine: Tirzepatide vs. Semaglutide, A Narrative Review of Clinical Trials

Related Resources

• Tirzepatide Medication Guide
• Mounjaro Medication Guide

Related Articles

• Semaglutide vs. Tirzepatide
• The SURMOUNT Trials
• Ozempic vs. Mounjaro

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Download DietApp.com to track your own progress alongside the evidence behind your treatment.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

Last medically reviewed and updated: July 11, 2026.